The Green Shift: How a Federal Cannabis Reclassification Could Reshape Medicine, Markets, and Medicare
Introduction A seismic shift is brewing in the corridors of federal drug policy, promising to ripple through laboratories, stock tickers, and medicine cabinets nationwide. The potential move to reclassify cannabis from Schedule I to Schedule III represents far more than bureaucratic paperwork. It is a pivotal moment that could unlock unprecedented medical research, reshape senior…